Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil

NCT00006251 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT00006251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00006251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2000
Completion date
Not reported
Enrollment
21 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute undifferentiated leukemia, adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, childhood burkitt lymphoma, childhood diffuse large cell lymphoma, childhood grade iii lymphomatoid granulomatosis, childhood immunoblastic large cell lymphoma, childhood myelodysplastic syndromes, childhood nasal type extranodal nk/t-cell lymphoma, chronic myelomonocytic leukemia, cutaneous b-cell non-hodgkin lymphoma, de novo myelodysplastic syndromes, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, hepatosplenic t-cell lymphoma, intraocular lymphoma, juvenile myelomonocytic leukemia, mast cell leukemia, myelodysplastic/myeloproliferative neoplasm, unclassifiable, myeloid/nk-cell acute leukemia, nodal marginal zone b-cell lymphoma, noncutaneous extranodal lymphoma, peripheral t-cell lymphoma, post-transplant lymphoproliferative disorder, previously treated myelodysplastic syndromes, primary systemic amyloidosis, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade iii lymphomatoid granulomatosis, recurrent adult hodgkin lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, recurrent childhood anaplastic large cell lymphoma, recurrent childhood grade iii lymphomatoid granulomatosis, recurrent childhood large cell lymphoma, recurrent childhood lymphoblastic lymphoma, recurrent childhood small noncleaved cell lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent renal cell cancer, recurrent small lymphocytic lymphoma, recurrent/refractory childhood hodgkin lymphoma, refractory chronic lymphocytic leukemia, refractory hairy cell leukemia, refractory multiple myeloma, small intestine lymphoma, splenic marginal zone lymphoma, stage ii multiple myeloma, stage iii multiple myeloma, t-cell large granular lymphocyte leukemia, testicular lymphoma, waldenström macroglobulinemia